News

Investigational antibody rozanolixizumab (UCB7665) has proven safe and effective in treating symptoms associated with myasthenia gravis (MG), Phase 2 results show. Based on the results of the MG0002 Phase 2 study (NCT03052751), biopharmaceutical company UCB plans to accelerate the development of rozanolixizumab with a confirmatory study…

Gut microbiota is altered in people with myasthenia gravis (MG), opening the door for exploring the use of microbiota-modulating therapies, like probiotics, as potential ways of better managing the disease. Results of the pilot study, “Fecal microbiota profile in a group of myasthenia gravis patients,” were published in…

Half a year has gone by since disgraced pharma executive Martin Shkreli was sentenced to seven years in federal prison for securities and wire fraud while heading San Diego-based Retrophin. As founder and CEO of another company (then known as Turing Pharmaceuticals), in late 2015 Shkreli bought the rights…

Patients with facioscapulohumeral dystrophy (FSHD) — a type of muscular dystrophy — can develop myasthenia gravis, possibly because of underlying immune dysfunction. A letter to the editor describing the case, titled “A case of facioscapulohumeral muscular dystrophy and myasthenia gravis with positivity of anti-Ach receptor antibody: a fortuitous association?” was published…

Myasthenia gravis patients have a greater risk of having autoimmune rheumatic diseases, especially those who underwent a thymectomy, according to researchers in Taiwan. Their study, “Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study,” was published in the journal Rheumatology.